Oct 25, 2026 · 4 min listen · Last updated October 25, 2026
From storyflo. This is your daily audio brief. Chloe, October 25th. The morning read — ten things in health worth the eight minutes. Let's get into it. First, from Kitchen Projects. KP+: Grape and Tonka Custard Pie. Today’s KP+ features a delightful recipe from Bronwen Wyatt, following her recent pie crust edition.
Listen · storyflo · health and longevity
Daily Health & Wellness Brief · October 25th
0:00-3:56
Pick your daily storyteller
Subscribe to match with Theo, Jessica, Chloe, Mason, Brock — your voice, every brief.
Daily Health & Wellness Brief · October 25th · Storyflo
culture
Audio pre-rendered by Storyflo · cached + delivered from the edge
KP+: Grape and Tonka Custard Pie
Today’s KP+ features a delightful recipe from Bronwen Wyatt, following her recent pie crust edition. She’s sharing a Grape and Tonka Custard Pie that promises to be a treat. The newsletter expresses gratitude to its readers, emphasizing the community aspect that makes it all possible. Caitlin, today’s recipe tester, has already given it a go, hinting at the pie’s deliciousness. If you’re looking for something unique to bake, this could be a fun addition to your repertoire. Keep an eye out for the full recipe and enjoy the process of making something special!
Bronwen's diving into a mini-series on American pie, starting with pie crust basics. She’s aiming for a sturdy single-crust recipe that can handle the peak pie season. While reminiscing about her love for British baking, she reflects on the stark differences between American and British pies, noting that American pies tend to be flakier and richer, evolving from medieval styles that didn’t prioritize the crust.
To create her ideal pie crust, Bronwen tested various methods, including mixing by hand versus a food processor, and experimenting with different types of butter and even adding an egg yolk. She’s focused on achieving a crust that’s both tender and resilient enough to support liquid fillings. The journey promises to be delicious and informative, perfect for pie lovers looking to elevate their baking game.
STAT+: After a cancer vaccine’s first success, the race is on to expand the impact
Hey! So, I saw this really interesting update about a cancer vaccine. Basically, there was a big trial, a pivotal one, that just showed some good results. They combined a personalized mRNA vaccine with a standard cancer drug, Keytruda, for melanoma patients. And it actually reduced the risk of the cancer coming back or death by 42% compared to just using Keytruda alone.
This is pretty significant because, honestly, developing effective cancer vaccines has been a really tough road for decades. People have been trying for a hundred years, and it hasn't really panned out until now. So, this is a genuinely big step forward.
The exciting part is that the researchers and doctors are already talking about how to start using this in practice for melanoma. And even more broadly, they're thinking about whether this kind of approach could work for other types of cancer too. It's still early days for that broader application, but the potential is definitely there.
The article dives into the experience of individuals who identify as AuDHD—those who are both autistic and have ADHD. It highlights the disconnect many feel after receiving a diagnosis; while it provides clarity about their neurodivergent wiring, it often leaves them grappling with deeper feelings of exhaustion, grief, or hypervigilance that the label alone doesn’t explain.
The author, a licensed clinician, introduces a framework called neurocomplexity, which aims to bridge this gap. They emphasize that while having AuDHD wiring isn’t caused by trauma, living in a world that doesn’t accommodate this wiring can lead to trauma-like adaptations. This perspective combines both nature and nurture, suggesting that understanding one’s neurotype involves recognizing the lived experiences that shape it.
Ultimately, the framework seeks to validate those who feel that their diagnosis doesn’t fully capture their journey, offering a more comprehensive understanding of their experiences.
#ESMO26: Pfizer looks beyond lung cancer flop as BioNTech, Bristol Myers show early activity
Pfizer is shifting its focus after a setback in non-small cell lung cancer, highlighting a post-hoc analysis that suggests some earlier-line patients might still benefit from their treatment. This kind of analysis looks back at data to find patterns, so while it’s promising, it’s worth noting that it’s not definitive evidence.
Meanwhile, BioNTech and Bristol Myers Squibb are reporting early signs of effectiveness in their cancer treatments. These findings are still in the early stages, but they’re generating some excitement in the oncology community. It’s always interesting to see how companies pivot and adapt after challenges, and these developments could lead to more options for patients down the line.
It seems like the article you wanted to discuss is behind a paywall or restricted access, so I can't pull any specific details from it. However, if it’s about leaked data on an mRNA vaccine, I can share some general insights.
mRNA vaccines, like those for COVID-19, have been studied extensively, showing effectiveness in preventing severe illness. Most of the data comes from large clinical trials and ongoing observational studies. If there are new findings or leaked data, it’s crucial to consider the source and context. Leaks can sometimes misrepresent the findings or lack the peer review process that validates research.
If you’re curious about specific aspects of mRNA vaccines or any recent developments, I’d be happy to chat about that!
Send this story to anyone — or drop the embed into a blog post, Substack, Notion page. Every play sends rev-share back to storyflo · health and longevity.